October 26, 2017
2 min read

Patients with cancer history receive less care for acute MI

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Guideline-recommended treatment for acute MI was given less to patients who had a history of cancer, according to a study published in European Heart Journal: Acute Cardiovascular Care.

“It is well-known that cancer patients may have an increased risk of cardiovascular disease as a result of their treatment,” Dragana Radovanovic, MD, head of AMIS Plus Data Center in Zurich, said in a press release. “However ... little is known about the treatment and outcomes of cancer patients who have an acute myocardial infarction.”

Sabine Rohrmann , P h D, MPH, of the division of chronic disease epidemiology at the University of Zurich, and colleagues analyzed data from 35,249 patients who had an acute MI (STEMI or non-STEMI) from the AMIS Plus registry in Switzerland. Among the cohort, 5.6% had a history of cancer.

Patients with and without a history of cancer had different baseline characteristics, including STEMI, age, BMI, diabetes, hypertension and smoking. Most of the differences disappeared after propensity-score matching except for BMI and differences in MI risk factors.

PCI was performed less in patients with a history of cancer vs. those without a history (OR = 0.76; 95% CI, 0.67-0.88). Patients with a history of cancer were given P2Y12 blockers (OR = 0.82; 95% CI, 0.71-0.94) and statins (OR = 0.87; 95% CI, 0.76-0.99) less frequently compared with those without a history of cancer.

Complications during hospitalization occurred more often in patients with a history of cancer vs. those without a history. The rate of in-hospital mortality was higher in patients with a history of cancer (OR = 1.45; 95% CI, 1.17-1.81) compared with those who did not have a history of cancer. Cardiac death was the main cause of mortality for both groups and did not significantly differ between them (OR = 0.68; 95% CI, 0.37-1.25).

“Numerous advances in the treatment of [acute] MI have occurred over the past few decades, and treatment of [acute] MI patients in Switzerland has substantially changed over the past 15 years in accordance with the recommended guidelines of evidence-based medicine,” Rohrmann and colleagues wrote. “However, [acute] MI remains an important cause of mortality and morbidity in the general population worldwide, and the application of evidence-based therapies for STEMI patients in real-world practice continues to be inconsistent, particularly for vulnerable populations such as women or the elderly.” – by Darlene Dobkowski

Disclosures: The authors report no relevant financial disclosures.